BA
VIRX

BlackRock Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

BlackRock Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$8K Hold
67
– – ﹤0.01% 3594
2016
Q3 		$10K Hold
67
– – ﹤0.01% 3575
2016
Q2 		$8K Hold
67
– – ﹤0.01% 3616
2016
Q1 		$8K Hold
67
– – ﹤0.01% 3609
2015
Q4 		$13K Hold
67
– – ﹤0.01% 3587
2015
Q3 		$11K Buy
67
+28
+72% +$10.1K ﹤0.01% 3646
2015
Q2 		$25K Sell
39
-118
-75% -$62.7K ﹤0.01% 3451
2015
Q1 		$81K Buy
157
+41
+35% +$20.7K ﹤0.01% 3126
2014
Q4 		$62K Sell
116
-305
-72% -$137K ﹤0.01% 3232
2014
Q3 		$631K Sell
421
-694
-62% -$1M ﹤0.01% 1781
2014
Q2 		$1.53M Sell
1,115
-516
-32% -$599K ﹤0.01% 1258
2014
Q1 		$2.26M Sell
1,631
-4,890
-75% -$5.69M ﹤0.01% 1150
2013
Q4 		$6.49M Sell
6,521
-354
-5% -$366K 0.01% 933
2013
Q3 		$7.16M Sell
6,875
-562
-8% -$600K 0.01% 885
2013
Q2 		$8.1M Buy
+7,437
New +$8.29M 0.01% 835

Other funds holding VIRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock Advisors's VIRX Position: Q4 2016 in Review

BlackRock Advisors held its Viracta Therapeutics, Inc. Common Stock (VIRX) position steady in Q4 2016 at 67 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #3594.

BlackRock Advisors first reported a position in VIRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $8.1M in Q2 2013. 45 funds tracked by Wall St. Rank hold VIRX as of Q4 2016.

  • BlackRock Advisors held 67 shares of Viracta Therapeutics, Inc. Common Stock worth $8K as of Q4 2016.
  • BlackRock Advisors left its Viracta Therapeutics, Inc. Common Stock share count unchanged in Q4 2016.
  • Viracta Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3594 holding.
  • BlackRock Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $8.1M in Q2 2013.
  • 45 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.